COMMUNIQUÉS West-GlobeNewswire

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

12/12/2024 - 22:05

Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby equity purchase [...]

Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual Meeting

12/12/2024 - 22:04

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the global leader in at-home EEG and AI-powered brain health analytics, presented two scientific posters at the American Epilepsy Society (AES) Annual Meeting [...]

Boundless Bio Announces Pipeline and Leadership Updates

12/12/2024 - 22:01

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through [...]

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

12/12/2024 - 22:01

PDUFA goal date is July 27, 2025 COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its [...]

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

12/12/2024 - 22:00

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

12/12/2024 - 22:00

Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF [...]

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

12/12/2024 - 22:00

Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]

Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 11 décembre 2024

12/12/2024 - 22:00

Daix (France), New York City (New York, Etats-Unis), le 11 décembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]

VelaLabs Announces Strategic Partnership with EarlyHealth Group to Support Biological Drugs Development

12/12/2024 - 21:22

VIENNA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- VelaLabs GmbH, a leading provider of analytical and quality services for biopharmaceutical development, has signed a Memorandum of Understanding (MoU) with EarlyHealth Group to [...]

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

12/12/2024 - 20:32

Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: [...]

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

12/12/2024 - 19:30

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion’s Board of Directors for delay in [...]

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research

12/12/2024 - 18:37

ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024 , held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements [...]

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

12/12/2024 - 18:05

Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for [...]

EssilorLuxottica: EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi)

12/12/2024 - 18:00

EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi) Paris, France (12 December 2024) – EssilorLuxottica announced today that its near-term greenhouse [...]

EssilorLuxottica: Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi)

12/12/2024 - 18:00

Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi) Paris, France (12 décembre 2024) – EssilorLuxottica a [...]

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

12/12/2024 - 16:15

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings [...]

ACARIZAX® approved in Europe for treatment of young children

12/12/2024 - 16:06

ALK ( ALKB:DC / OMX: ALK B ) today announced that its European regulatory filing for ACARIZAX ® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health [...]

Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors

12/12/2024 - 16:05

Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- [...]

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

12/12/2024 - 15:30

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]